SMAD2 and pulmonary arterial hypertension: When these effectors were antagonized with a ligand trap, SMAD2/3signaling was attenuated and experimental PH was reversed, suggesting restorationof balance to amongst BMP versus TGFβ/Activin/GDF as a therapeutic targetin PAH.